The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Aberrant Ras/Raf/mitogen-activated protein kinase (MAPK) signaling is a hallmark of metastatic prostate cancer (PCa).
• SET and MYND domain 3 (SMYD3), a lysine methyltransferase, is overexpressed in PCa and linked to disease severity.
• The precise molecular role of SMYD3 in PCa tumorigenesis remains undefined.

Purpose of the Study:

• To elucidate the molecular function of SMYD3 in promoting prostate cancer progression.
• To investigate the role of SMYD3-mediated methylation of MAP3K2 in PCa phenotypes.
• To identify potential therapeutic vulnerabilities associated with the SMYD3-MAP3K2 signaling axis.

Main Methods:

• Utilized PCa cell lines and mouse xenograft models to study SMYD3 function.
• Assessed SMYD3's methyltransferase activity and its impact on tumor-associated phenotypes.
• Investigated the interaction between SMYD3 and MAP3K2, and its downstream effects on epithelial-mesenchymal transition (EMT) and vimentin expression.

Main Results:

• SMYD3 methyltransferase activity is essential for driving tumor-associated phenotypes in PCa.
• SMYD3-dependent methylation of MAP3K2 promotes EMT-associated behaviors by modulating vimentin levels.
• The SMYD3-MAP3K2 signaling axis forms a positive feedback loop, sustaining high SMYD3 levels.

Conclusions:

• SMYD3 plays a critical role in prostate cancer metastasis through its methyltransferase activity.
• Targeting the SMYD3-MAP3K2 pathway presents a potential therapeutic strategy for metastatic PCa.
• Understanding SMYD3's mechanistic functions offers new insights into PCa signaling and therapeutic opportunities.